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A B S T R A C T
Cancer biomarkers represent a revolutionary advance toward personalised cancer treatment, promising
therapies that are tailored to subgroups of patients sharing similar generic traits. Notwithstanding the
optimism driving this development, biomarkers also present an array of social and ethical questions, as
witnessed in sporadic debates across different literatures. This review article seeks to consolidate these
debates in a mapping of the complex terrain of ethical and social aspects of cancer biomarker research.
This mapping was undertaken from the vantage point offered by a working cancer biomarker research
centre called the Centre for Cancer Biomarkers (CCBIO) in Norway, according to a dialectic move between
the literature and discussions with researchers and practitioners in the laboratory. Starting in the lab, we
found that, with the exception of some classical bioethical dilemmas, researchers regarded many issues
relative to the ethos of the biomarker community; how the complexity and uncertainty characterising
biomarker research inﬂuence their scientiﬁc norms of quality. Such challenges to the ethos of cancer
research remain largely implicit, outside the scope of formal bioethical enquiry, yet form the basis for
other social and ethical issues. Indeed, looking out from the lab we see how questions of complexity,
uncertainty and quality contribute to debates around social and global justice; undermining policies for
the prioritisation of care, framing the stratiﬁcation of those patients worthy of treatment, and limiting
global access to this highly sophisticated research. We go on to discuss biomarker research within the
culturally-constructed ‘war on cancer’ and highlight an important tension between the expectations of
‘magic bullets’ and the complexity and uncertainty faced in the lab. We conclude by arguing, with
researchers in the CCBIO, for greater reﬂexivity and humility in cancer biomarker research and policy.
ã 2016 The Author. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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Cancer research has witnessed important developments over
the last two decades towards personalised medicine, which aims to
tailor cancer treatments to subgroups of patients sharing similar
genetic traits. Biomarkers have been an important tool in this
transition, and are often presented as a revolutionary new
technology used for patient assessment to help determine
predispositions to particular types of cancer, to screen and
diagnose cancer types and stages, to estimate the disease
prognosis, to predict the most effective course of treatment, and
to monitor cancer recurrence [1]. There is a noticeable techno-
optimism regarding cancer biomarkers, especially in policy reports
where they are anticipated to facilitate a higher-quality, safer and* Corresponding author at: Centre for the Study of the Sciences and the
Humanities, Allegaten 34, 5020 Bergen, Norway.
E-mail address: anne.blanchard@uib.no (A. Blanchard).
http://dx.doi.org/10.1016/j.nbt.2016.06.1458
1871-6784/ã 2016 The Author. Published by Elsevier B.V. This is an open access articlemore efﬁcient treatment of cancer while decreasing health care
costs [2–4].
However, as for many revolutionary new technologies, bio-
markers bring with them a host of ethical and social consider-
ations. This has seen a small but growing body of literature
addressing some of these particular issues, ranging across different
disciplines including health economics and policy (see e.g. [5,6]),
bioethics (see e.g. [7]), and philosophy of medicine (see e.g. [8,9]).
Arguably, the cross-disciplinary nature of these issues has led to a
fragmented literature, without an overview of this complex ethical
and social terrain. We seek to contribute to the literature through a
mapping of this terrain, and the interrelatedness of the ethical and
social issues in it.
Another contribution of this paper is that it takes its point of
departure in the ethical concerns and issues of scientiﬁc quality
met in the cancer biomarker lab. This anchors the mapping of
ethical and social aspects of cancer biomarkers in their laboratory
context; while also providing practitioners and researchers
working in the ﬁeld a legitimate guide for their personal reﬂections
on the ethical aspects and scientiﬁc norms of their everyday work. under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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from discussions within a working cancer biomarker research
centre called the Centre for Cancer Biomarkers (CCBIO), in Bergen,
Norway; and the cross-disciplinary literature. The author has been
eliciting reﬂections among CCBIO researchers on the ethical and
social aspects of their work, from the lab looking out; these
reﬂections being triggered by some key themes in the literature. At
the same time, the diverse considerations raised by CCBIO
researchers have in turn framed the literature review. In this
way, the review emerged from a dialectic move between literature
and practice.
This paper explores the social and ethical issues that have been
formulated through the practice-literature interaction, and high-
lights the interrelatedness of these issues. Here, we explore social
issues both in terms of those faced in wider society, and more
speciﬁcally those faced by the scientiﬁc community exploring
biomarkers; what can be considered as the ethos, or norms,
shaping that community. The exploration will be structured
around three clusters. After elements of background and method
in Section 2, Section 3 explores issues related to the ethos of
science and ethical concerns met in the lab. Beginning from these
issues of the ethics and ethos of science, Section 4 explores the
ethical aspects of cancer biomarkers in a context of social and
global justice, while Section 5 focuses on the social aspects of
cancer biomarkers, in particular the cultural meanings of cancer.
Finally, Section 6 concludes by arguing that the complexities,
uncertainties and questions of scientiﬁc quality surrounding
biomarker research demand humility and reﬂexivity, both in the
lab and in policy-making.
2. Background and method
2.1. From blockbuster drugs to personalised medicine
In the last two decades, cancer research and care has been
undergoing important changes as a result of an increased
awareness of the complexity and heterogeneity of cancer (see
e.g. Nature’s special issue [10]). Traditional forms of cancer therapy
associated with ‘blockbuster’ chemotherapy drugs have been
increasingly criticised for leading to under- or over-treatment of
patients, with a higher risk of adverse and sometimes lethal side-
effects [11]. This ‘one-size-ﬁts-all’ approach does not account for
the heterogeneity within the primary tumour (intratumoural
heterogeneity), between the primary tumour and metastases
(intertumoural heterogeneity), or between cancer patients (intra-
patient heterogeneity) [12]. In response, an expanding body of
literature from the biomedical sciences (see e.g. [11,13]) has put
forward ‘personalised’ or ‘tailored’ medicine as an alternative
model for cancer research and care. Personalised medicine aims to
adapt cancer treatments to sub-groups of patients who share
similar genetic traits and tumour characteristics, and to provide
patients with the right drug, at the right time and dose [11].
One clinical way of implementing personalised medicine is
through cancer biomarkers. Biomarkers are substances or pro-
cesses found in patients’ tissues, blood or other body ﬂuids, which
indicate the presence of cancer in the body. According to Mishra
and Verma [14], biomarkers can either be a molecule (like a protein
or an antibody) secreted by a tumour, or a speciﬁc response of the
body to the presence of cancer, such as biochemical changes like
gene expressions and mutations. In a metaphorical way, cancer
biomarkers are the ‘ﬁngerprints’ of different tumours, and can help
stratify patients according to their genetics and tumour character-
istics. Research on cancer biomarkers is in its infancy, and so far
only a few biomarkers have entered clinical practice. One
successful cancer biomarker is the protein HER-2, which is
overexpressed in about 20–25% of women with breast cancer,indicating that they have higher chances to react well to the drug
trastuzumab. Another example is the normal (non-mutated) KRAS
gene, present in about 60% of patients with metastatic colorectal
cancer, that indicates that only these patients are likely to respond
to the drugs cetuximab and panitumumab.
Cancer biomarkers offer the promise of treatments that are
both more efﬁcient and safer for the patients, and cheaper than
traditional cancer therapies in the long run, considering techno-
logical advances and reduced harmful side-effects in the patients.
Biomarkers are thus a source of hope for cancer patients and
medical practitioners alike, and have increasingly received both
considerable political attention and public funding, including in
Norway.
2.2. The Centre for Cancer Biomarkers (CCBIO) and integrated ELSA
research
The Centre for Cancer Biomarkers (CCBIO) is a research centre
based in Bergen, Norway. It aims to improve biological under-
standing, early diagnosis and treatment of cancer by using novel
biomarkers. It was funded in 2013 by the Research Council of
Norway for a period up to ten years, and received the status of
Norwegian Centre of Excellence. Based at the University of Bergen,
with most activities taking place at the Faculty of Medicine and
Dentistry, the CCBIO consists of nine principal investigators and
gather in total about 140 people including medical researchers,
clinicians, bioinformatics researchers, economists and social
scientists. Research activities are organised around three core
programmes: pre-clinical studies, clinical studies and biomarkers.
To integrate the three programmes, speciﬁc research projects have
been initiated at CCBIO, that look for instance at the tumour-
microenvironment interactions or at the discovery and validation
of cancer biomarkers.
One particular characteristic of CCBIO is that it has integrated
the study of the ethical, legal and social aspects of its research; also
known as ELSA research. ELSA research looks at the ethical, legal
and social aspects around emerging technologies in the various
ﬁelds of biotechnology, nanotechnology or biomedicine. ‘Integrat-
ed ELSA’ in particular encourages a dialogue between the ELSA
researchers and the researchers developing the new technology
under scrutiny. The ethical, legal and social questions are identiﬁed
in close cooperation, so that they can be reﬂexively discussed and
integrated to the research process at an early stage, thus
encouraging reﬂections about scientiﬁc responsibility [15]. Con-
cretely for CCBIO, this means that alongside its three core research
programmes, it also has an ELSA team, led by a Professor in
philosophy of science, working with a post-doctoral researcher,
myself as the author of the paper with a background in Science and
Technology Studies, and a part-time research assistant. The ELSA
team looks mainly at the ethical and social considerations around
cancer biomarkers, and does so in an integrated way with the
cancer biomarker researchers. This is why the mapping in this
paper takes its point of departure in the ethical and social concerns
met in the lab, to then look out to broader, ethical and social
aspects of cancer biomarkers.
2.3. Method and purpose for the mapping
Mapping the terrain of the ethical and social aspects of cancer
biomarkers was the starting point to the integrated ELSA research
in CCBIO. The ELSA team ﬁrst teased out key ethical and social
considerations around cancer biomarkers from the cross-disci-
plinary literature, and presented these key themes to CCBIO
researchers to help trigger their own reﬂections and discussions.
Our interactions mainly took place during bimonthly junior
scientist seminars, CCBIO’s annual symposia and during a PhD
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informal discussions between the CCBIO junior researchers and
myself.
Second, on the basis of the interest triggered by these
interactions, I undertook during the period of June to October
2014, a set of 15 informal one-hour discussions across CCBIO’s
various research programmes, including biomarker research for
melanoma, breast and gynaecologic cancers, and spanning early
career scientists (PhDs and post-docs) to senior scientists
(researchers and clinicians) (see Table 1). The discussions were
not recorded as they were informal, but extensive notes were taken
and the quotes of the CCBIO researchers that ﬁgure in this paper
were all approved by their authors. These discussions introduced
me to the ethical and social concerns met in the lab, with a
particular focus on questions of complexity, uncertainty and
quality in research on cancer biomarkers. The output of the
discussions in turn helped steer and frame the mapping of ethical
and social aspects around cancer biomarkers presented in this
paper. This integrated ELSA approach has allowed us to achieve a
more contextualised and comprehensive mapping, that can be
seen as a legitimate guide for researchers and practitioners in the
ﬁeld of cancer biomarkers to further reﬂect on the social and
ethical concerns they meet in their everyday work.
3. Ethics and ethos in the lab
One cluster of issues relates to the conduct of science itself;
what could broadly be discussed as the ethics and ethos of
scientiﬁc research. In the lab, the investigation into the social and
ethical issues of cancer biomarkers came to focus on the norms
that shape this scientiﬁc community, particularly relative to
notions of complexity, uncertainty and quality, while not
dismissing the ethical character of these norms. As a new ﬁeld,
biomarker research explicitly tries to address cancer as heteroge-
neous, and therefore highly complex; introducing signiﬁcant
attendant uncertainties. These uncertainties have implications
for the norms by which this scientiﬁc community judges the
quality of their research, and its ethical conduct. As a biomarker
researcher, navigating within these uncertainties means to
carefully examine the research assumptions, method and objec-
tives. Are the research assumptions not too simplistic with regard
to the complex biology of cancer? Is the research method
transparent about its limitations in the face of non-linear systems?
Are the research objectives feasible, and how will research results
contribute to the ﬁeld and to society at large, knowing that they
will be surrounded by signiﬁcant uncertainties? As we see in this
section, it is crucial for researchers and practitioners of the ﬁeld to
be critical and transparent about their ways of working with
uncertainties, as this impacts the quality and relevance of research
results, and puts into question whether investing in research on
cancer biomarkers is a good use of public money. Indeed, the
plasticity and heterogeneity of tumour cells make it very difﬁcult
for biomarkers to ﬁnd a clinical application (see e.g. [16,17]). CCBIOTable 1
The CCBIO informants quoted in this paper.
Informant A 
Informant B 
Informant C 
Informant D 
Informant E 
Informant F 
Informant G 
Informants H and I 
Informant J 
Informant K researchers have reﬂected upon these questions and have raised
four concerns related to the quality and ethical conduct of their
science, discussed in this section in the light of the literature.
3.1. The problem of reproducibility
Taking the complexity and heterogeneity of cancer and its
associated uncertainties as a point of departure, a ﬁrst family of
issues related to the ethics and ethos of science is the difﬁculty to
reproduce scientiﬁc experiments and results in cancer biomarker
research.
3.1.1. Lack of standardised methods
A ﬁrst barrier to reproducibility is the fact that research
routines, quality standards and technologies available change from
a laboratory to another. Informant A states: “In biomarker studies
on the same biomarker, there is often a lack of standardised
methods for measuring the biomarker under study. The impor-
tance of assay development is maybe underestimated in biomarker
development.” This concern is echoed in the literature, with
Mishra and Verma [14] pointing at the non-uniform preparation
and storage of cancer samples across laboratories, and Allison [18]
arguing that different laboratories may have different quality
standards.
3.1.2. Limited quality and availability of tumour samples
A second barrier to reproducibility is the quality and availability
of tumour samples used for research. Tumour tissues that are
collected as part of diagnostic routines are preserved in formalin
before they are embedded in parafﬁn blocks and stored. Additional
tissues are sometimes collected solely for research purposes, and
conserved as fresh frozen tissue. But these samples used for
research only are sparse as their storage needs to be organised in
research biobanks and requires informed consent. Further, there
are also practical issues to sampling for research purposes: it has to
be organised without disturbing clinical standard procedures and,
depending on the localisation of the lesion, it can be challenging to
obtain a sufﬁcient amount of tissue. As Informant B explains: “As
researcher, I am fully aware of the fact that the clinicians need to
ensure that sufﬁcient tissue is available for optimal diagnosis for
treatment planning. Therefore, the use of tissue for diagnostic
purposes has the highest priority to beneﬁt the patient. Only if
feasible and considered completely safe for the patient, can
researchers use snap-frozen tumour tissue for molecular and
genomic studies. For instance in cervical cancer, some tumours are
too small to allow clinicians to collect snap-frozen tissue for
research purposes.” The problem with parafﬁn-embedded tissues,
however, is that they are manipulated and contaminated by the
parafﬁn and formalin. This concern of limited quality and
availability of samples for research is found in the literature,
particularly the slow enrolment of patients and hence the lack of
fresh tissue samples for cancer research (see e.g. [19]).Post-doctoral researcher working on breast cancer
PhD candidate working on gynaecologic cancer
Post-doctoral researcher working on breast cancer
Post-doctoral researcher working on transcapillary exchanges
PhD candidate working on melanoma
Researcher working on gynaecologic cancer
Clinician part of the CCBIO network
Two PhD candidates working on breast and endometrial cancer
PhD candidate working on melanoma
Post-doctoral researcher working on transcapillary exchanges
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A third barrier to reproducibility is the representativity of the
tumour samples used for biomarker research. It is indeed difﬁcult
to collect samples that account for the intratumoural heterogene-
ity, as recalled by Informant B: “The specimens sampled for
molecular and genomic studies are collected based on a
macroscopic assessment by the responsible surgeon. These
samples are not used before the routine diagnosis has been
secured by the team of pathologists and discussed with the
clinicians. Even if we aim to study representative tumour areas,
heterogeneity may introduce bias. It is after all only a small part of
the tumour that may be explored, and this part may not reﬂect all
parts of the entire tumour.” Bearing in mind that tissue samples
might not account for intratumoural heterogeneity, and consider-
ing as well the heterogeneity of tumours between patients, we
quickly realise the difﬁculty to replicate research results and to
validate conclusions for clinical practice.
3.1.4. Environmental sensitivity in pre-clinical models
A fourth barrier to reproducibility raised by CCBIO researchers
concerns pre-clinical models, and in particular the environmental
sensitivity of the mice’s biological traits. Studies by Prinz et al. [20]
and Begley and Ellis [21] show that despite careful and systematic
approaches to reproduce results from landmark pre-clinical
studies, with “the same laboratory, the same people, the same
tools and the same assays, with experiments separated by 5
months”, there were important differences in the results. For
instance, the Amgen scientists in the study of Begley and Ellis [21]
were able to reproduce results of only 6 pre-clinical studies out of
the 53 they emulated. This is in part explained by the mice’s
sensitivity to the environment, which means that different
experimental conditions, such as different labs, may lead to
different results. Furthermore, as explained by Informant C: “Even
in a group of mice born of the same womb from the same
pregnancy, and living in the same cage, the results of a particular
experiment would vary within that group; potentially because
inbred mice are not always identical like the cloned ones.”
3.1.5. Publication bias towards positive results
Finally, a ﬁfth barrier to reproducibility is found in the very
competitive climate in the ﬁeld of cancer research. Many in CCBIO
researchers recognise the pressure to publish positive results, as
they are more easily accepted into highly ranked journals. In the
literature, the bias towards publishing positive results in the
medical sciences is also discussed, with for instance, Yaqub [22]
revealing that about half of all clinical trials undertaken in the USA
are not being published. This is both due to the publication bias
towards positive results, as well as to the intense competition in
cancer research that can lead to “negligence over the control or
reporting of experimental conditions” [20]. In addition to making it
very difﬁcult to reproduce results, this creates an illusion that the
biology behind the results is less complex and more certain than it
actually is. The problem of ‘anchoring’ reinforces this bias; it is
indeed relatively difﬁcult to publish “results that contradict data
from high-impact journals or the currently established scientiﬁc
opinion in a given ﬁeld” [20]. In response to this pressure to publish
positive results, scholars argue for more opportunities to present
negative data, in articles and at conferences for instance, and state
that publication institutions should encourage the sharing of
imperfect, complex and non-linear results [21].
3.2. Reducing complexity
Recognising the heterogeneity of cancer, a second family of
issues related to the ethos and ethics of science concerns the
necessary reduction of complexity when undertaking cancerbiomarker research. This reduction of complexity is especially
noticeable in mouse models, but also appears in the concept of
biomarker itself.
3.2.1. Mice are not men
Mouse models are used for cancer biomarker research at the
pre-clinical level. Mice comprise a simple model in which a
scientiﬁc hypothesis can be tested under conditions where the
known variables of the experiment can be controlled. The mice
share the same genetic background and only ones of the same
weight, age and gender are employed in a particular experiment.
The mice are bred and maintained under the same conditions
(temperature, food, etc.). Informant D explains that researchers
want the variations of the genome to be minimal in mice, as
working with all the variables found in real animals would make it
impossible to arrive at, and repeat, certain observations. However,
as lab mice are simpler than humans and do not reﬂect genetic
variability, we can wonder whether the results are still valid for
higher levels of complexity. Another issue related to the ethics and
ethos of science raised by Informant D is the relevance of sub-
cutaneous models, which are the most common pre-clinical
models in cancer research. In these models, the tumour is injected
under the skin of the mouse, to evaluate the spread of the tumour
over time. However, this is different to a tumour that grows in an
organ: in patients, the microenvironment inﬂuences the way the
tumour develops and how it spreads. It is thus difﬁcult to interpret
results from subcutaneous models. Concerns around the relevance
of mouse models are also raised in the literature, with Strand [23]
asking whether it is possible to justify the biological relevance of
knowledge obtained under artiﬁcial conditions, and a recent study
by Seok et al. [24] claiming that the genomic responses in mouse
models poorly mimic human inﬂammatory diseases like cancer.
The literature has also plenty of examples showing the non-
linearity and emergent properties between pre-clinical and clinical
studies. Among them, the striking 2006 case of the antibody
TGN1412, tested in phase I trials on six human volunteers at a dose
that was 500 times lower than the dose proven safe in several pre-
clinical studies. Soon after being given the dose, all six volunteers
“faced life-threatening conditions involving multi-organ failure for
which they were moved to intensive care units” [25]. This implies
that ensuring the reproducibility of results in the lab does not
necessarily mean that these results will be successfully translated
into clinical studies. To prevent disasters like in the TGN1412 trial,
measures like Informant A suggests for trial design could be taken:
“Clinical studies should have a more adaptive design, allowing for
changes in the course of the trial, as new knowledge comes in or
unexpected effects are experienced. As always, patient safety has
top priority.”
3.2.2. Evaluation of biomarkers by immunohistochemistry
Evaluating the presence of cancer biomarkers in tissues is often
done by immunohistochemistry, which, put very simply, is a
process to detect biomarkers in a tissue sample by staining them. It
is then possible to evaluate the cancer biomarker’s ‘expression’,
which is the protein expression in the tissue, on a scale from 0
(negative) to 3+ (strongly positive) (see for instance the scoring
guidelines for the HER2 biomarkers [26]). However, it is difﬁcult to
rate ambiguous results on this simple scale, and Informant E
argues: “The problem is that the grading from 0 to 3 of the protein
expression in the light microscope is semi-objective. People may
give different numbers for the same sample.” Further, like
evaluating the intensity of a colour on a tissue sample, assessing
the difference between “a faint/barely perceptible membrane
staining” (which is 1+ on the scale) and “a weak membrane
staining” (which is the lower end of 2+ on the scale) is also
subjective. This discussion would not bear signiﬁcant importance if
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score in the tissue sample, patients will be offered more or less
aggressive drugs, or no treatment at all. This ethical concern of
where to place the cut-off was ﬁrst coined by Callahan [27] under
the label of ‘ragged edges’, and then taken up by Fleck (see for
instance [8]). According to the latter, there is no clear, well-deﬁned
line between strong responders and non-responders; rather, there
is a continuum of responses, which means that those who are on
the ragged edge will ‘fall off’ and not get access to the treatment.
We discuss in Section 4 the ethical concerns associated with
ragged edges in a context of health care rationing.
3.2.3. Mismatch between simple biomarkers and complex biology
Biomarkers try to indicate whether a patient is likely to develop
cancer, will beneﬁt from a particular treatment, or is at risk of
relapsing. An iconic biomarker that is frequently referred to is the
protein HER2, for breast cancer. From the discovery of HER2 in
1982, to the cloning of the HER2 gene, its testing in Phase I to III
trials, the creation of the companion test, and the approval of the
drug, Herceptin, in 1998, only 16 years passed [28]. However, such
success stories are rare in cancer biomarker history. As Informant A
observes: “There is a mismatch between simple, linear biomarkers
and the heterogeneity and complexity of tumours. Such ideal
biomarkers do not ﬁt the complexity of human biology.” This is
conﬁrmed by Informant E: “There is a high complexity in cancer,
and probably one biomarker is not likely to give you the perfect
prediction because so many processes are involved.” The plasticity
of tumour cells explains in great part why even the most efﬁcient
targeted drugs fail to act as a long lasting cure, and “why even the
best personalised approaches mostly delay disease progression but
rarely eradicate it” [29]. Against the complexity and heterogeneity
of cancer tumours, what then is a good biomarker? Informant A
asks: “Is a reliable biomarker measurement of only one protein or
several? The mRNA expression of 10 or 100 genes?” We will see in
Section 5 that describing biomarkers as simple may give patients
the illusion that their cancer type can be neatly categorised, and
that choosing a treatment option can be equally straightforward.
3.3. The problem of validation
With the heterogeneity inherent to cancer biology and the
subsequent challenges to work with this complexity and reproduce
results, it is very difﬁcult to validate cancer biomarkers and put
them into clinical practice. There are further barriers to the
validation of new cancer biomarkers, as notes Informant A:
“Validating a biomarker demands a lot of efforts but it is maybe not
seen as innovative enough to be published. Therefore it is easier to
jump to research on a new biomarker.” Scholars also underline the
lengthiness of the validation process [30,19] and its costs, with
Brodniewicz and Grynkiewicz [31] arguing that it takes up to one
billion US$ to launch a new drug in the USA. There is also the risk to
engage in a validation process for a cancer biomarker that may be
too expensive or inconvenient to use, that may lack clinical utility,
or even, that may lead to harm through over-treatment [32].
Another barrier to the validation of cancer biomarkers is the
lack of dialogue between clinicians and researchers. As Informant F
observes: “My job as a researcher is to discover biomarkers and not
to check whether they are implemented or not. But clinicians are in
contact with patients, so they understand the context of patient
care.” Likewise, in the literature, authors encourage greater
dialogue between clinicians, researchers and patients in the
context of cancer research and care: “Scientists beneﬁt from
learning about clinical reality. Physicians need better knowledge of
the challenges and limitations of preclinical studies. Both groups
beneﬁt from improved understanding of patients’ concerns” [21].Because of the difﬁculty to validate cancer biomarkers, less than
1% make it to clinical practice [32]. As we will discuss in Section 4,
this poses a question of social justice, in particular whether
allocating public money to cancer biomarker research is a fair and
wise choice.
3.4. Informed consent, data privacy and incidental ﬁndings
A last concern met in the lab, of a more classical bioethical
nature, relates to how informed consent forms are collected from
cancer patients, and how the digital datasets generated from their
samples are managed and protected. Unlike the three previous
subsections, this subsection relates less directly to the ethos of the
scientiﬁc inquiry, but the ethical concerns discussed here are
exacerbated by the questions of complexity, uncertainty and
quality.
Cancer research is based on the availability of biological
samples, and demands that in addition to the samples collected for
diagnostic purposes, supplementary samples are taken for
research purposes. To ensure a responsible and ethical collection
of samples for research purposes, patients receive an informed
consent sheet, including information on the purpose of the
research and its potential beneﬁts (making clear that these will
likely to go to future patients). But even if patients can withdraw
their consent at any time, and even if refusing to give their consent
in the ﬁrst place has no impact on the way they are treated,
Informant G wonders: “We are very aware of the fact that patients
are vulnerable at the time when we need to collect their informed
consent. They are newly diagnosed with cancer, and our
experience is that most are willing to contribute to research. It
is important that they have easy access to withdraw their consent if
they change their opinion.” Indeed, there is a relation of
dependence between the researchers and the patients, and one
must be careful not to “push informed consent onto the patient”.
Another ethical issue concerns new genome sequencing
methods and the large amount of genetic data they generate. As
Informants H and I note: “We are about to reach the point where
whole genome sequencing is becoming a standard in cancer
research.” This ﬁrst poses the problem of incidental ﬁndings: when
using new genome sequencing methods, incidental ﬁndings are
more likely to occur. Incidental ﬁndings, discovered during the
course of a research study, concern a research participant and have
potential health or reproductive importance for him, but are
beyond the scope of the study [33]. How then to manage such
ﬁndings? Should the patient know about them, and if yes, under
which conditions: if there is an acute and imminent risk of genetic
disease? If there is a risk of passing the disease to the next
generations? Should the decision be made according to a risk
threshold? Second, new genome sequencing methods also pose
the question of data privacy. From a single, physical entity, the
tumour itself, which is kept in a biobank at the hospital, new
genome sequencing methods derive digitalised ﬁles containing
large datasets. Informants H and I explain: “This raises the question
of storage and protection of the material. A physical tumour sample
is stored in one location, and can be easily protected, but once
sequencing analysis has been performed, the information lying
within the tissue is transformed into a readable DNA sequence.”
One risk is that these hackeable digital data fall in the hands of
employers or insurance companies, who may act counter to the
interests of the patient [34].
3.5. In sum: complexity, uncertainty and quality in biomarker research
In moving between the literature and informal discussions with
CCBIO researchers, it emerged that most of the social and ethical
issues in the lab centre on the ethos of the scientiﬁc community,
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issues of informed consent, data privacy and incidental ﬁndings.
Essentially, what do the particular complexities and uncertainties
surrounding cancer biomarkers imply for scientiﬁc norms of
quality? We saw that for reasons ranging from technical aspects
(for instance the lack of standardised methods across laboratories)
to the intrinsic complexity of the biology of cancer (that leads
researchers of the ﬁeld to use simplifying pre-clinical models), it is
difﬁcult to reproduce and validate scientiﬁc results, and thus to put
them into clinical practice. Such issues of quality in cancer
biomarker research tend to remain implicit because they are not
‘ethical’ in the sense that they are not often dealt with by ethical
committees or ethical guidelines. However, these issues do have an
ethical component in that they underpin more classical ethical
debates around prioritisation of care and social and global justice
for instance. They also have a social component to the extent that
we consider the biomarker community as guided by these norms.
Indeed, they are all the more important, and deserving of attention,
in that they do not explicitly enter the everyday decisions in the
lab, and it is possible to continue producing papers without too
much attention to them.
4. Social and global justice
The issues of complexity, uncertainty and quality that are met in
the biomarker lab reach out to contribute to broader social and
ethical questions. Cancer biomarkers are very high on political
agendas and are often described in the media as ‘magic bullets’ (see
e.g. the cover of Time Magazine of May 2001, depicting Imatinib
pills as ‘ammunition’ targeting diseased cells). This hype around
cancer biomarkers gives a strong incentive for researchers to work
within this ﬁeld, but as noted by Informant A, it is not propitious to
critical thinking: “We all run into the mainstream lane of research
on biomarkers, and too rarely are we taking distance, thinking
outside the box.” Arguably, taking the time to think about the
broader social aspects of cancer biomarkers in the light of the
ethical and quality concerns met in the lab seems necessary. What
are the costs of personalised cancer therapies? Who has access to
them? Can we, and should we pay for the health care needs of all
cancer patients? What about the access of personalised medicine
in third world countries? These ethical and social concerns,
clustered around the theme of social and global justice, are
discussed by CCBIO researchers as well as the literature.
4.1. Prioritising health care
The rationing and allocation of healthcare resources according
to priority criteria (in particular the severity of the disease, the
effectiveness and the cost of the drug) is inevitable in a context
where health care resources, or rather our willingness, as a society,
to pay for all the healthcare needs of every citizen, is limited [35]. It
is for instance hard to justify paying for a treatment that will allow
one individual to live a few weeks longer, while the same amount
of money could be spent on the total healthcare fees of one single
person for one year. Utilitarian ideals, whereby a moral choice is
one that produces the most ‘utility’, are strongly built into Western
health care decision-making processes. Accordingly, health econ-
omists assess how many Quality Adjusted Life Years (QALYs) a
patient can get through a particular treatment option, and at which
cost. These economic tools allow decision-makers to visualise the
opportunity costs of their prioritisation choices: if money is
allocated to a particular cancer drug, then X number of vaccines, or
X number of heart operations will not be funded. These trade-offs
allow maintaining the sustainability of health care systems. The
question of prioritisation is particularly stringent for cancer for
three main reasons.First, cancer most commonly affects older patients. According
to the latest report from the American Cancer Society [36], 78% of
all cancers in the US are diagnosed in people above 55 years old,
and ﬁgures are similar in Norway [37]. Further, the UK Macmillan
Cancer Support [38] shows that only 10% of people aged 25–49
years old and less than 2% of people under 25 years old are
diagnosed with cancer. In addition, elderly cancer patients are
often more vulnerable than younger patients to the toxicity of
cancer drugs [39]. This can translate into serious side-effects that
will necessitate additional resources to tackle them. Further, these
costs may later multiply where ex-cancer patients develop other
age-related diseases, like dementia, requiring speciﬁc health
resources and care [8].
The second reason why prioritisation questions are particularly
stringent for cancer is the high costs of therapies, especially
personalised therapies. The targeted cancer therapies that are
approved by the American Food and Drug Administration, cost
between US$ 70,000 and US$ 130,000 for a course of treatment
[40]. In Norway, Informant J explains that the new targeted therapy
for aggressive melanoma with the drug Vermurafenib “offers a
median progression free survival of 6–7 months, for a cost of 21800
NOK [about US$ 2600] per week.” These costs are signiﬁcant, and
examples from the literature emphasise the need to ration the
access to personalised therapies in order to keep a sustainable
health care system. Fojo and Grady [41] show that keeping a
patient with epithelial lung cancer alive for one year costs US$
800,000; which, when extrapolated to all the Americans who die
from cancer each year, would bring the costs to US$ 440 billion per
year. Jackson and Sood [42] look at how one year of treatment with
Bevacizumab, costing around US$ 50,000, corresponds to the
median household income in the US in 2008.
Third, what adds further heat to the questions of prioritisation
of care is the fact that several studies show that the expensive
cancer therapies only yield a few weeks to a few months of survival
(see e.g. [42,43]). Considering the cost of the therapies and the age
and vulnerability of the patients, this poses the question whether
public money dedicated to targeted cancer therapies could be
better allocated to other health care needs, where it would buy
more high-quality life years at a lower cost [40].
However, prioritisation of care is not only based on utilitarian
criteria, but also on considerations of fairness and compassion. As
Informant J argues: “Even if the price for Vermurafenib is high, it is
a revolutionary therapy because before that, nothing existed for
these patients who wanted and needed a therapy.” Justice as
fairness is what we turn to in the following section.
4.2. Social justice and fairness
In parallel with debates on how to prioritise health care
resources in an efﬁcient way, emerge debates of just and fair access
to cancer therapies. Arguably, personalised cancer therapies can
lead to the stratiﬁcation of society along three axes.
Firstly, and related to the debate on prioritisation of health care,
personalised therapies are mainly targeted at and beneﬁting older
patients, most of them above 55 years old. This constitutes a
powerful group in society, who is vocal in the media, recounting
their life with cancer, their struggles, their hopes and despair. Such
stories are part of a powerful discourse, what Brekke and Sirnes
[44] term the ‘sovereignty of suffering’, and bear a lot of weight in
decision-making processes, as we will see in Section 5. But are
elderly cancer patients sometimes over-shadowing less powerful
and visible patients? Are their needs prioritised over other,
younger patients’ needs?
Secondly, personalised cancer therapies can exacerbate gaps
between the wealthy or well-insured, and poorer or less well-
insured cancer suffers. Targeted cancer therapies could potentially
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the USA and in Europe, a burden that will need to be met by
increased taxes or privatisation through the insurance sector. As
Fleck [8] notes: “The well insured will increasingly resist paying
such taxes because they would not see themselves as beneﬁciaries
of those programs.” However, it is not even sure whether private or
public insurers will be able to reimburse these costs [45]. Insurers
facing these costs in the USA have begun off-loading the expenses
onto patients, with an estimated of 62% of all personal bankrupt-
cies attributable to medical costs, principally cancer [42]. This all
amounts to personalised cancer therapies being solely accessible
to the wealthy.
The third axis relates less to the age or ﬁnancial status of
patients, and more with how patients are technically stratiﬁed in
the lab. As we saw in Section 3.2, classifying cancer patients with
biomarkers into categories of strong, weak or non-respondents is
not straightforward. Fleck [8] argues that the “clinical reality in
metastatic cancer is most often a continuum of responses from
weak to strong”. In this case, where do we draw the cut-off line
between those who will be granted access to the newest
personalised cancer therapy, and those who won’t; those along
the ragged edge? Callahan [27], who ﬁrst coined the concept of
ragged edge, argues that wherever we draw the line, there will
always be people on the other side; and we should try and accept to
live with ragged edges: “We can accept [the ragged edge], not
because we lack sympathy for those on it, but because we know
that, once a ragged edge is defeated, we will then simply move on
to still another ragged edge, with new victims – and there will
always be new victims.”
Personalised cancer medicine may provoke inequalities of
access: mainly for older, richer patients who are lucky enough to be
assigned to the ‘safe’ side of the clinical cut-off. It is possible to
argue that money invested in other diseases or in younger patients
would be a fairer use of healthcare resources. However, cancer
patients, whatever their age or social status, are faced with the
prospect of a terminal outcome. Targeted therapies often represent
their last chance of survival, and arguably they deserve compassion
[40]. Balancing compassion and the fair allocation of health
resources is difﬁcult, and demands, as we will see in Section 4.4,
some human judgement and debates on what it is to be a fair and
caring society.
4.3. Global justice
The two debates around the prioritisation of health care and the
fair access to health care resources take a particular character
when they zoom out from focussing on one developed country
context to consider questions of global justice.
The utilitarian debates around the distribution of scarce health
resources at the global scale have been phrased by some scholars in
terms of ‘global availability’, or “the problem of incentivising new
medicines for diseases that afﬂict primarily or exclusively the
developing world” [46]. These scholars argue that global health
systems are organised such that ﬁnancial incentives privilege
diseases more prevalent in the developed world: “drugs are not
developed for the health needs of the poor because incentives for
pharmaceutical innovation are built around patients’ ability to
pay” [47]. For example, according to Trouiller and Olliaro [48], of
the 1223 new drugs that were sold worldwide during 1975–1996,
less than 1% tackled tropical diseases. More recent numbers
indicate that 100 million dollars per year worldwide are spent on
tropical disease research versus over 3 billion dollars per year in
the US alone for cancer research [49] (see also [50]).
In a context of global justice, the debate about fair access to
personalised medicine is shifted from the access between the well-
insured and the others, to the developed and developing countries.Expensive personalised cancer therapies pose questions of ‘global
access’, or “the problem of ensuring that the poor can obtain
medicines that already exist” [46]. According to a 2009 report from
the United Nations, about two billion people do not have access to
essential medicines, and “improving access to medicines could
save 10 million lives a year” [51]. As noted by Informant K, most
cancer biomarkers are not simple, and they therefore cannot be
easily used in clinical practice in the third world, because of their
high costs and the sophisticated technologies they require for their
implementation.
4.4. In sum: issues in the lab contributing to global debates
We can see how issues of complexity, uncertainty and quality in
the biomarker lab can contribute to debates around social and
global justice for cancer research and care. Looking at the
prioritisation of care, framed by policy-makers in terms of the
severity of the disease, the effectiveness and the cost of the drug,
we see how the complexities and uncertainties in the lab can act to
undermine this prioritisation process. The QALY system is based on
an instrumental rationale, predicated on clear causation and a
certainty of outcomes; it is difﬁcult to weigh up alternative options
for medical spending when it is not clear what will come of this
spending. Looking to social justice and fairness, we see how some
scholars have framed this debate around stratiﬁcation; elevating
the powerful group of older patients exercising their sovereignty of
suffering, and driving wedges between those who can afford
treatment and those who cannot. Questions of complexity,
uncertainty and quality in the lab also act to formalise (and
normalise) this stratiﬁcation relative to how the ‘ragged edge’ is
drawn between patients who will or will not respond to treatment.
Finally, issues of global justice are often framed relative to global
availability and access. Scholars discuss this availability and access
as limited by pharmaceutical business models, the powerful voice
of the developed country patients, but also by the complexity,
uncertainties and issues of quality in the lab. As noted by Informant
K, research on cancer biomarkers demands sophisticated equip-
ment and a depth of expertise that cannot be readily set up via a
simple technology transfer.
In the light of these social and global justice debates, many
CCBIO researchers agree that it is important to question the extent
to which their work inﬂuences the fairness and sustainability of
health systems. Fleck [52] encourages medical students to engage
in health policy debates, otherwise “political interests or economic
interests will dominate and potentially corrupt the values that are
supposed to be central to the practice of medicine”. Issues around
social and global justice indeed beneﬁt from the participation of
cancer researchers in democratic deliberations. However, one
should not consider these deliberations or increased training for
medical students as ways to arrive at a clean answer. For complex
health justice questions, characterised by ragged edges, there is no
one technical ‘formula’ to provide us with clear answers. Callahan
[27] believes it is rather a question of human judgement; where
the ‘reasonable’, ‘sensible’ and ‘prudent’ standards that society
decides to live by, have to be discussed.
5. The cultural meaning of cancer
This section takes a critical perspective on the importance of
cancer research in Western societies. The social constructions of
cancer, often seen as an invasive and unfair disease that we ought
to control, have inﬂuenced the development of cancer research, in
particular towards personalised therapies. In turn, personalised
cancer research has also inﬂuenced the social constructions
around cancer, giving the illusory hope that it can be understood,
predicted and controlled. This critical section is different to the
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on the social and cultural constructions of cancer. These
constructions and discourses are important, to the extent that
they frame the ethical and social concerns in Sections 3 and 4.
5.1. War spending
We have seen in Section 4.3 on global justice that despite a
much lower incidence worldwide, more money is spent on cancer
than on tropical diseases. We saw as well that this was in part due
to a lack of research and innovation incentives when the patients’
ability to pay is low. However, how can we explain that spending on
personalised cancer drug in developed countries increases every
year by 14% [42], especially considering that most of these drugs
only give a few more months of survival? How can we explain that
the global market for cancer drugs has reached US$ 100 billion
annually in 2014, and that it is expected to reach up to US$ 147
billion by 2018 [53]? Is it only because patients, or the country they
live in, can afford these expensive therapies? Is it because of the
huge hope placed on biomedical research? Is it out of fear, despair
or guilt of loosing the ‘war against cancer’? Arguably, spending on
cancer drugs is high because of all of these reasons and probably
others. But one powerful reason is the social construct of cancer:
how it is depicted in the media, in movies and in the literature; the
place and shape it takes in social narratives and imaginaries. In
other words, the metaphors that are used to refer to cancer, and the
cultural meaning they lend to this disease. As explained by Helman
[54], diseases that are difﬁcult to understand, predict and cure
“come to symbolise many of the more general anxieties that some
people have, such as a fear of the breakdown of ordered society, of
invasion or of divine punishment”. As a result, war narratives are
often used for describing cancer: ‘invasion’ and ‘battle’ were
metaphors for cancer and its treatment used by President Nixon in
his 1971 declaration of ‘War on Cancer’ [54]. Another telling
example from the 1950s, as Cold War America faced the
destruction of its social ideals, shows how cancer embodied these
fears: “It was the ultimate emergence of the enemy from within  a
marauding cell that crawled out of one’s own body and occupied it
from the inside, an internal alien” [55]. According to this social
construct, war can either be lost or won, and patients are left with
only two options: surrender or ﬁght it to the bitter-end.
5.2. Medicalisation
The ‘war on cancer’ is presented as a noble enterprise; someone
who defeats cancer is a survivor who has managed to keep the
disease at bay, and someone who has cancer should at least put up
a good ﬁght. As Informant G explains: “It is my impression that only
a decade ago, chemotherapy was discontinued after a few rounds
of treatment. Today, many women and their doctors are willing to
try additional rounds of chemotherapy, also in the context of little
evidence for clinical beneﬁt. Indeed, there is a literature on
practices in the USA where chemotherapy is used right up until the
last week of life, when there is limited evidence of beneﬁts to the
patient [63]. This introduces concerns around effective and fair use
of health resources, as well as the impact of aggressive cancer
therapies on the quality of life of patients at the end of life.
Pharmaceutical companies have an interest in reinforcing the
social construct of cancer as a monster that we ought to control, as
there are important proﬁts to be made in selling screening tests
and drugs (see Section 5.1). Via marketing and direct-to-consumer
advertising, ‘big pharma’ contributes to a culture of medicalisation,
where illnesses and diseases alike are managed through clinical
examinations, screening tests and drugs [49]. Screening tests for
estimating healthy patients’ risk factors for diseases, in particular
cancer, have indeed become an important part of the medicalactivity [56]. They are generally depicted as a simple, potentially
life-saving action, which might augment the feeling of guilt among
society: since it is so easy to undergo screening tests and get
checked for a particular cancer biomarker, one has a nearly moral
obligation to take them (see the discussion of Sharon Kaufman
[64]). However, the associated harmful side effects are not often
talked about: the stress caused to patients that are waiting for
results [57], the change in self-conception and how others relate to
someone who is categorised as being sick, and last but not least,
“the harms of false alarms, over-diagnosis, and unnecessary
treatment” [58], what Fredriksen [59] also calls ‘snowballing
medicalisation’. In addition, it is easy to think that biomarker
screening tests can disclose everything; but these tests are only
looking at a small spot, when countless mechanisms actually enter
into play in the development of a cancer tumour.
5.3. Hope
The medicalisation of cancer is not only enforced because of big
pharma’s inﬂuence on the social constructs of cancer. It also stems
from a trend towards more mathematical models in biomedicine,
as asked by policy-makers, which “implies a focus on simple,
controllable and predictable objects” [23]. This gives an illusion
that human biology is simpler than it actually is, and gives hope
that all cancers might be curable in a near future. It is frequent to
read that the ultimate goal of personalised cancer medicine is to
one day be able to read and manage the billions of data points for
each individual in such way that it will predict any transitions into
disease [34], or to one day ﬁnd solutions to the problem of cancer
drug resistance such as identifying the full range of resistance
mechanisms [60]. This hope and optimism towards biomedical
research brings with it the belief that the needs of every cancer
patient can be met if health care is delivered in an efﬁcient way.
Patients’ hope, important ﬁnancial support and new promising
research on cancer come together to constitute what Brekke and
Sirnes [44] call the ‘emerging economy of hope’. This in part
unrealistic ‘agenda of hope’ has not been thoroughly scrutinised
and questioned in the light of the ethical dilemmas seen in
Sections 3 and 4; rather, it is left unleashed, as “dreams and longing
command money, not limits and realism” [27]. In this context, new
communities appear, gathering patients hoping for a cure tailored
to their own type of cancer, pharmaceutical companies seemingly
eager to help these patients, and research groups demanding more
means and resources in order to develop these personalised cures
[44]. These communities are well connected and informed on the
latest scientiﬁc advances, and have a powerful voice in policy
debates. According to these communities, “there are no inherent
obstacles or pitfalls of science that could stop the realisation of
revolutionary cures” [44]; rather, it is the politicians that refuse to
invest the necessary resources into every type of cancer.
However, the hope and belief that biomedical research, if
granted with the necessary means, will one day be able to deliver
high-quality personalised cures to every cancer patient, is
misguided. As Callahan wrote already in 1990: “We cannot pursue
a limitless idea of quality and hope to do so efﬁciently. We cannot
achieve both maximum quality and full equity” [27]. Excessive
hope and optimism towards biomedical research leads to a low
tolerance for uncertainty and a mismatch between what patients
expect in terms of possibility of treatments and what doctors can
offer them. As Informant G puts it: “In some patient-doctor
relations, it may be a challenge to balance evidence for clinical
beneﬁt with unrealistic expectations conveyed in the news,
sometimes hyping hopes based on small studies. Also, research
on the Internet by the patient and their relatives may contribute to
unrealistic expectations. Building mutual trust over time is
important in this setting.” Acknowledging the randomness of
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“adults must accept responsibility for their own situation, no
matter how much bad luck they have suffered from” [61], might
help reintroduce some human judgement – ‘realism’, ‘reason’,
‘sensibility’ and ‘prudence’ [27] – into the debates of what we, as a
society want from cancer research and care.
5.4. In sum: waging total war
We saw in Section 5 how the war on cancer is inspiring cancer
sufferers to battle the enemy within to the bitter end, and ‘not go
gentle into that good night’. Such total war demands our full
arsenal of weapons and tactics, legitimising a medicalisation that
promotes screening tests and preventive medicine in addition to
the normal treatments after diagnosis of cancer. However,
medicalisation brings with it potential side-effects, for instance
to our self-perception and perception by others, or indeed our
conception of what constitutes a healthy person. One major side-
effect that has accompanied medicalisation is the hope and
expectations foisted on cancer research and therapy. Emerging
communities have mobilised to argue for the limitless potential of
medical science. This makes clear an important tension between
the expectations of ‘magic bullets’ and the complexity and
uncertainty faced in the lab. The imaginary of cancer research
still outstrips the struggles in the lab and the quality of biomarkers
produced.
6. Conclusion
This review set out to explore the particular ethical and social
aspects of cancer biomarkers, through a dialectic move between
the literature and informal conversations in a working biomarker
centre. In doing so, it adopted a unique perspective from inside the
lab, looking out. Notwithstanding some more classical bioethical
dilemmas, this perspective regarded many of the issues in the lab
relative to the ethos of the cancer biomarker community; how the
complexity and uncertainty characterising cancer biomarker
research inﬂuence their norms of quality. Looking out from the
lab, we saw how this ethos can inﬂuence, or indeed complicate,
wider social and ethical debates, nationally and globally. In turn,
we saw that socio-cultural constructions of cancer and imaginaries
of biomedical science have acted to shape, and sometimes conﬂict
with, the ethos in the lab. By incorporating an ELSA component to
its centre, the CCBIO has taken steps to make these implicit issues
explicit, in order to discuss them.
This paper joins other scholars in arguing that the complexity,
uncertainty and questions of scientiﬁc quality in biomarker
research demand more humility and reﬂexivity, both in the lab
and in the research policy decisions that promote cancer
biomarkers. Reﬂexivity implies that the biomarker research
community is able to reﬂect on the underlying principles and
purposes of their ﬁeld, and on the potential impacts of their
research on society. Humility implies awareness “about both the
limits of scientiﬁc knowledge and about when to stop turning to
science to solve problems” [62]. In recognising the fallibility of
science, particularly in such a bold new ﬁeld as biomarkers, Kern
[32] notes: “A greater recognition of biomarker failures is
constructive and acknowledges the richness of biologic, technical,
and philosophical complexity, the full appreciation of which could
improve the management of scarce research resources.” In
emphasising that many social and ethical considerations lie
outside the realms of science, Fleck [8] argues that even if we
were to discover perfect biomarkers, we would be left with the
moral and political problems of ragged edges, pricing human life
and deciding whether to grant desperate patients their last chance
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